BioSpace News Archive

Coinciding with Melanoma Awareness Month, the Melanoma Research Alliance, the largest non-profit funder of melanoma research, announced funding for 27 research grants totaling $13,046,774 to support new research aimed at advancing melanoma prevention, diagnosis and treatment.

Avenge Bio, Inc. (“Avenge” or the “Company”), a biotechnology company developing the LOCOcyte™ immunotherapy platform for the precision administration of potent immune effector molecules to treat solid tumors, today announced that two abstracts were selected for presentation as posters at the 25th Annual American Society of Gene & Cell Therapy (ASGCT) Meeting.

The CMD is a live event, open for physical attendance at Hotel Continental in Oslo, Norway, as well as a live webcast.

GigaGen Inc. announced the publication of a research article titled, “Predicting antibody binders and generating synthetic antibodies using deep learning,” in the peer-reviewed journal mAbs.

Athira Pharma, Inc. announced, based on the preliminary vote count provided by its proxy solicitor, that Athira’s shareholders have approved the election of all three of Athira’s highly qualified, independent director nominees – Joseph Edelman, John M. Fluke, Jr. and Grant Pickering – to the company’s board of directors.

The genetic engineering has enabled the identification of several genetic diseases as well as the novel genes which are associated with their development.

Poly ADP-Ribose Polymerase (PARP) inhibitors are long chain containing 17 enzymes that combine several (poly) units of ADP-ribose in a chain and transfer them to the target proteins.

Kirsten rat sarcoma viral oncogene homologue (KRAS) is one of the most often mutated genes in several cancers such as lung cancer, colorectal cancer, pancreatic cancer, and others.

Pursuant to Article 241-2 of the AMF General Regulations, the purpose of this description is to present the objectives and terms of the share repurchase program of Inventiva S.A. as approved by the Ordinary General Meeting of May 19, 2022.

MDxHealth SA announces that Palmetto GBA, a Medicare Administrative Contractor that assesses molecular diagnostic technologies under its MolDX program, has finalized a foundational Local Coverage Determination for Molecular Biomarkers to Risk-Stratify Patients at Increased Risk for Prostate Cancer that covers the indication for our SelectMDx® for Prostate Cancer test.